NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free TLSI Stock Alerts $9.31 -0.04 (-0.43%) (As of 12:24 PM ET) Add Compare Share Share Today's Range$9.31▼$9.5650-Day Range$9.06▼$10.2552-Week Range$3.32▼$16.24Volume73,874 shsAverage Volume37,240 shsMarket Capitalization$249.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get TriSalus Life Sciences alerts: Email Address Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About TriSalus Life Sciences Stock (NASDAQ:TLSI)TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More TLSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLSI Stock News HeadlinesApril 5, 2024 | morningstar.comTriSalus Life Sciences IncApril 3, 2024 | benzinga.comTriSalus Life Sciences Stock (NASDAQ:TLSI), Earnings Estimates, EPS, and RevenueApril 29, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 2, 2024 | insidermonkey.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2023 Earnings Call TranscriptApril 1, 2024 | markets.businessinsider.comTriSalus Life Sciences, Inc. Q4 sales increaseApril 1, 2024 | finance.yahoo.comTriSalus Reports Q4 and Full Year 2023 Financial Results and Business UpdateApril 1, 2024 | finance.yahoo.comTriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ...March 26, 2024 | finance.yahoo.comTriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific MeetingApril 29, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 21, 2024 | finance.yahoo.comTriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific MeetingMarch 11, 2024 | businesswire.comTriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for "Nelitolimod" as the Nonproprietary Drug Name for SD-101March 7, 2024 | businesswire.comTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101February 29, 2024 | businesswire.comTriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver TumorsJanuary 24, 2024 | seekingalpha.comTriSalus Life Sciences: Rocket-Like Recovery Could Be An Inflection PointJanuary 9, 2024 | morningstar.comTriSalus Life Sciences Inc TLSIDecember 17, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)December 15, 2023 | msn.comTriSalus Life Sciences files to sell 5.9 million shares for holdersDecember 15, 2023 | msn.comMyomo, Aileron Therapeutics among healthcare moversDecember 13, 2023 | finance.yahoo.comTriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023See More Headlines Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/29/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CUSIPN/A CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net MarginsN/A Pretax Margin-318.89% Return on EquityN/A Return on Assets-166.18% Debt Debt-to-Equity RatioN/A Current Ratio1.42 Quick Ratio1.25 Sales & Book Value Annual Sales$18.51 million Price / Sales13.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.98) per share Price / Book-9.51Miscellaneous Outstanding Shares26,760,000Free Float6,368,000Market Cap$249.40 million OptionableNot Optionable Beta0.65 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Mary T. Szela B.S.N. (Age 60)M.B.A., CEO, President & Director Comp: $880.67kMr. Sean Edward Murphy (Age 71)CFO & Director Comp: $628.75kDr. Steven C. Katz F.A.C.S. (Age 49)M.D., Chief Medical Officer & Chairman of Scientific Advisory Board Comp: $849.89kMs. Jodi Devlin (Age 62)President of Commercial Operations Mr. Alan C. MendelsonSecretaryKey CompetitorsAngioDynamicsNASDAQ:ANGOSight SciencesNASDAQ:SGHTUtah Medical ProductsNASDAQ:UTMDPulmonxNASDAQ:LUNGInovio PharmaceuticalsNASDAQ:INOView All CompetitorsInstitutional OwnershipTyche Wealth Partners LLCSold 16,664 shares on 4/23/2024Ownership: 0.037%Tyche Wealth Partners LLCBought 26,664 shares on 1/30/2024Ownership: 0.101%View All Institutional Transactions TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed in 2024? TriSalus Life Sciences' stock was trading at $8.45 at the beginning of the year. Since then, TLSI stock has increased by 10.3% and is now trading at $9.32. View the best growth stocks for 2024 here. When is TriSalus Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our TLSI earnings forecast. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) announced its quarterly earnings results on Monday, April, 1st. The company reported ($1.56) EPS for the quarter. The firm earned $5.72 million during the quarter. What guidance has TriSalus Life Sciences issued on next quarter's earnings? TriSalus Life Sciences issued an update on its fourth quarter 2023 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.7 million-$5.7 million, compared to the consensus revenue estimate of $5.5 million. Who are TriSalus Life Sciences' major shareholders? TriSalus Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Tyche Wealth Partners LLC (0.04%). How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLSI) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
